Jounce Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2013)
Status: Acquired by Redx Pharma Plc

Organization Overview

First Clinical Trial
2016
NCT02904226
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Jounce Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

ipilimumab (yervoy) (2 trials)

jtx-2011 (4 trials)

jtx-4014 (3 trials)

nivolumab (opdivo) (2 trials)

Drugs in Phase 1 Trials (2)

jtx-8064 (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 6